HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.

MLA

Gharib, Ehsan, et al. “HER2+ MCRC Patients with Exon 20 R784G Substitution Mutation Do Not Respond to the Cetuximab Therapy.” Journal of Cellular Physiology, vol. 234, no. 8, Aug. 2019, pp. 13137–44. EBSCOhost, https://doi.org/10.1002/jcp.27984.

APA

Gharib, E., Salmanipour, R., Nazemalhosseini Mojarad, E., Yaghoob Taleghani, M., Sarlak, S., Malekzade, M. M., Nasrabadi, P. N., Meiary, M. A., Asadzadeh Aghdaei, H., & Zali, M. R. (2019). HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy. Journal of Cellular Physiology, 234(8), 13137–13144. https://doi.org/10.1002/jcp.27984

Chicago

Gharib, Ehsan, Reza Salmanipour, Ehsan Nazemalhosseini Mojarad, Mohammad Yaghoob Taleghani, Saharnaz Sarlak, Moghani, Mona Malekzade, Parinaz Nasri Nasrabadi, Mohammad Amin Meiary, Hamid Asadzadeh Aghdaei, and Mohammad Reza Zali. 2019. “HER2+ MCRC Patients with Exon 20 R784G Substitution Mutation Do Not Respond to the Cetuximab Therapy.” Journal of Cellular Physiology 234 (8): 13137–44. doi:10.1002/jcp.27984.